Malaria vaccine - Dow AgroSciences

Drug Profile

Malaria vaccine - Dow AgroSciences

Latest Information Update: 19 Jan 2007

Price : $50

At a glance

  • Originator Dow AgroSciences
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 05 Jul 2000 The assets and technology of Axis Genetics have been sold to Dow AgroSciences
  • 10 Sep 1999 Suspended-Preclinical for Malaria in United Kingdom (Unknown route)
  • 10 Sep 1999 Axis Genetics has been placed into administration and a buyer is being sought for its business and assets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top